Thus, the observed relationship between reduced BOLD-LFOs and AD pathophysiology in APOE4 carriers may be related to changes in vascular function, astrocyte reactivity, or astrocyte-vascular interactions30. The gene discussed is APOE; the disease is Alzheimer disease.